High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2026Q4
FY2027Q1
FY2027Q2
464.52M
+9.65%
0.256
-1.7%
391.36M
+9.74%
0.152
+38.04%
393.82M
+8.87%
0.138
-8.08%
Estimates Revision
The market is revising Upward the revenue expectations for UiPath Inc. (PATH) for FY2026, with the revenue forecasts being adjusted by 1.26% over the past three months. During the same period, the stock price has changed by 60.84%.
Revenue Estimates for FY2026
Revise Upward
+1.26%
In Past 3 Month
EPS Estimates for FY2026
Revise Downward
-2.48%
In Past 3 Month
Stock Price
Go Up
+60.84%
In Past 3 Month
18 Analyst Rating
Wall Street analysts forecast PATH stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for PATH is 13.67 USD with a low forecast of 12.00 USD and a high forecast of 17.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
15 Hold
1 Sell
Hold
Current: 18.480
Low
12.00
Averages
13.67
High
17.00
Current: 18.480
Low
12.00
Averages
13.67
High
17.00
Wells Fargo
Michael Turrin
Equal Weight
maintain
$12 -> $14
2025-12-04
New
Reason
Wells Fargo
Michael Turrin
Price Target
$12 -> $14
2025-12-04
New
maintain
Equal Weight
Reason
Wells Fargo analyst Michael Turrin raised the firm's price target on UiPath to $14 from $12 and keeps an Equal Weight rating on the shares. The firm says that while Q4 guidance suggests further growth stabilization, it remains balanced at current levels as Wells awaits greater signs of traction around the company's RPA+AI vision.
Canaccord
Buy
maintain
$15 -> $19
2025-12-04
New
Reason
Canaccord
Price Target
$15 -> $19
2025-12-04
New
maintain
Buy
Reason
Canaccord raised the firm's price target on UiPath to $19 from $15 and keeps a Buy rating on the shares. The firm said the company demonstrated improving execution and continued signs of building momentum selling agentic capabilities in its FQ3'26. It was the first quarter in two years that net-new ARR has increased on a year-over-year basis, marking a significant milestone that gives credence to the company's strategy leaning into agentic automation and orchestration in a dynamic enterprise software market.
Barclays
Equal Weight
maintain
$14 -> $16
2025-12-04
New
Reason
Barclays
Price Target
$14 -> $16
2025-12-04
New
maintain
Equal Weight
Reason
Barclays raised the firm's price target on UiPath to $16 from $14 and keeps an Equal Weight rating on the shares post the Q3 report. The company reported another solid quarter and indicated that the business is stabilizing, the analyst tells investors in a research note.
RBC Capital
Sector Perform
maintain
$12 -> $14
2025-11-12
Reason
RBC Capital
Price Target
$12 -> $14
2025-11-12
maintain
Sector Perform
Reason
RBC Capital raised the firm's price target on UiPath to $14 from $12 and keeps a Sector Perform rating on the shares as part of a broader research note previewing Q3 results in the Software sector. Software volatility remains elevated on the AI trade as there is a crowding effect with AI winners, though the firm's checks for October off-quarter earnings were better than prior quarters, most notably from select cybersecurity vendors, as investors focus on ideas that can accelerate growth and benefit from AI trends, the analyst tells investors in a research note.
UBS
Sell
to
Neutral
upgrade
$10 -> $17
2025-10-23
Reason
UBS
Price Target
$10 -> $17
2025-10-23
upgrade
Sell
to
Neutral
Reason
UBS upgraded UiPath to Neutral from Sell with a price target of $17, up from $10, as the analyst resumed coverage of the stock. The outlook is "still mixed," but near-term GenAI risk fears appear "overdone," the analyst tells investors.
Canaccord
Buy
downgrade
$16 -> $15
2025-09-08
Reason
Canaccord
Price Target
$16 -> $15
2025-09-08
downgrade
Buy
Reason
Canaccord lowered the firm's price target on UiPath to $15 from $16 and keeps a Buy rating on the shares. The firm said UiPath demonstrated improving execution and early signs of building momentum selling agentic capabilities in its FQ2'26 with revenue of $362M, stable NRR at 108%, and non-GAAP operating income of $62M. The results, while not world-beating, demonstrate stability including some growth green shoots with large global enterprises while continuing to highlight strong profitability with a 25% TTM adjusted Free Cash Flow margin.
See All Ratings
Valuation Metrics
The current forward P/E ratio for UiPath Inc (PATH.N) is 26.42, compared to its 5-year average forward P/E of 116.63. For a more detailed relative valuation and DCF analysis to assess UiPath Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
116.63
Current PE
26.42
Overvalued PE
1073.98
Undervalued PE
-840.72
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
-148.81
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
544.63
Undervalued EV/EBITDA
-842.24
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
10.86
Current PS
0.00
Overvalued PS
20.72
Undervalued PS
1.00
Financials
Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
PATH News & Events
Events Timeline
(ET)
2025-12-04
16:20:00
Major Averages Close Little Changed as Jobless Claims Fall to 191,000
2025-12-04
12:10:00
UiPath Stock Rises 20.8% to $17.95
2025-12-04
12:00:00
Major U.S. Indices Little Changed as Investors Anticipate Fed Rate Cut
Sign Up For More Events
Sign Up For More Events
News
![[object Object]](https://d5bp8bijhhba2.cloudfront.net/image/cover_image/253091251371a31cdbb3a95c48204c738db125ef5a5743f543234435a87df026.jpg)
Preview
9.5
08:00 AMNASDAQ.COMPinnedReasons Behind Today's Surge in UiPath Stock
![[object Object]](https://d5bp8bijhhba2.cloudfront.net/image/cover_image/1b888a028682bdceec7b32ac71def304c5273eda25b9655d14f8557a4713e66c.png)
Preview
9.5
04:06 AMBenzingaPinnedUiPath Overcomes Growth Slowdown, Analysts Indicate Q3 as a Pivotal Moment
![[object Object]](https://d5bp8bijhhba2.cloudfront.net/image/cover_image/b50c2505918e49b359a1fd39439685465640394714622b8dfcd9f2221ebd86c8.png)
Preview
9.5
01:27 AMBenzingaPinnedUiPath Analysts Raise Predictions After Impressive Q3 Results
Sign Up For More News
People Also Watch
FAQ
What is UiPath Inc (PATH) stock price today?
What is UiPath Inc (PATH)'s business?
What is the price predicton of PATH Stock?
What is UiPath Inc (PATH)'s revenue for the last quarter?
What is UiPath Inc (PATH)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for UiPath Inc (PATH)'s fundamentals?
How many employees does UiPath Inc (PATH). have?